<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="4-part\PMC7283535\results\search\disease\results.xml">
  <result pre="the control of 16 major diseases, namely, smallpox, diphtheria, tetanus," exact="yellow fever," post="pertussis, Haemophilus influenzae type b disease, poliomyelitis, measles, mumps,"/>
  <result pre="type b disease, poliomyelitis, measles, mumps, rubella, typhoid, rabies, rotavirus," exact="hepatitis" post="B, pneumococcal, and meningococcal diseases. Noteworthy is the complete"/>
  <result pre="diseases. Noteworthy is the complete or partial eradication achieved for" exact="smallpox" post="and poliomyelitis, respectively (3). To counteract infectious diseases, the"/>
  <result pre="a number even, higher than the 8.2 million caused by" exact="cancer" post="today (9) (Figure 2). Figure 1 Life expectancy increase"/>
  <result pre="by mutation or post-translational modifications. (D) Resistance mechanism of Mycobacterium" exact="tuberculosis" post="to isoniazid drug mutations in the katG gene causes"/>
  <result pre="that are used as first line methods of treatment against" exact="gonorrhea" post="infection (47). The main lethal target of cephalosporins is"/>
  <result pre="be discovered soon, we may enter an era of incurable" exact="gonorrhea" post="infections (48). Therefore, understanding the mechanisms underlying the AMR"/>
  <result pre="also very effective in reducing AMR. For istance, vaccines against" exact="influenza" post="virus reduce the incidence of fever and sickness which"/>
  <result pre="Vaccines Attempts to &quot;vaccinate�? begin even before the Edward Jenner's" exact="smallpox" post="vaccination was introduced. In the 7th century, some Indian"/>
  <result pre="of variolation, consisting in the introduction of dried pus from" exact="smallpox" post="pustules into the skin of a patient, was practiced"/>
  <result pre="in 1796 he tested the protective effect of a prior" exact="cowpox" post="infection against smallpox by actively immunizing an eight-year-old-boy with"/>
  <result pre="tested the protective effect of a prior cowpox infection against" exact="smallpox" post="by actively immunizing an eight-year-old-boy with cowpox and then"/>
  <result pre="cowpox infection against smallpox by actively immunizing an eight-year-old-boy with" exact="cowpox" post="and then carrying out smallpox challenge (variolation) (72). In"/>
  <result pre="actively immunizing an eight-year-old-boy with cowpox and then carrying out" exact="smallpox" post="challenge (variolation) (72). In the 19th century, Louis Pasteur"/>
  <result pre="the induction of antibodies directed against invariable antigens (e.g., smallpox," exact="yellow fever," post="polio, rabies, mumps, measles, rubella, varicella, herpes zoster, hepatitis"/>
  <result pre="(e.g., smallpox, yellow fever, polio, rabies, mumps, measles, rubella, varicella," exact="herpes zoster," post="hepatitis A, and Japanese encephalitis). Therefore, vaccines that were"/>
  <result pre="yellow fever, polio, rabies, mumps, measles, rubella, varicella, herpes zoster," exact="hepatitis" post="A, and Japanese encephalitis). Therefore, vaccines that were developed"/>
  <result pre="effective immune response. This approach has been successfully applied to" exact="diphtheria" post="and tetanus, two diseases caused by bacterial toxins (75)."/>
  <result pre="new approach enabled the generation of the genetically detoxified Bordetella" exact="pertussis" post="toxin (76) and the recombinant hepatitis B surface antigen"/>
  <result pre="the genetically detoxified Bordetella pertussis toxin (76) and the recombinant" exact="hepatitis" post="B surface antigen (HBsAg) (77). Genetic engineering has also"/>
  <result pre="to develop genetic &quot;reassortants,�? as in the case of the" exact="influenza" post="attenuated vaccine or the rotavirus vaccine, which is based"/>
  <result pre="that have been efficiently used for the chemical conjugation are" exact="tetanus" post="toxoid (TT), diphtheria toxoid (DT), and a non-toxic cross-reacting"/>
  <result pre="efficiently used for the chemical conjugation are tetanus toxoid (TT)," exact="diphtheria" post="toxoid (DT), and a non-toxic cross-reacting mutant of DT"/>
  <result pre="of them, namely AS04, was used in 2005 for the" exact="hepatitis" post="B (HBV) vaccine and in 2007 for the human"/>
  <result pre="A, targeting TLR4), has been licensed for a vaccine against" exact="malaria" post="and herpes zoster vaccine. Also, it is currently used"/>
  <result pre="TLR4), has been licensed for a vaccine against malaria and" exact="herpes zoster" post="vaccine. Also, it is currently used in clinical trials"/>
  <result pre="H. influenzae and Moraxella catarrhalis, aimed to prevent exacerbation in" exact="chronic obstructive pulmonary disease." post="The TB vaccine phase 2b trial conducted in Kenya,"/>
  <result pre="Kenya, South Africa, and Zambia provided 54.0% protection in M." exact="tuberculosis" post="infected adults against active pulmonary tuberculosis disease. This vaccine"/>
  <result pre="provided 54.0% protection in M. tuberculosis infected adults against active" exact="pulmonary tuberculosis" post="disease. This vaccine is composed of the M72 recombinant"/>
  <result pre="54.0% protection in M. tuberculosis infected adults against active pulmonary" exact="tuberculosis" post="disease. This vaccine is composed of the M72 recombinant"/>
  <result pre="of the M72 recombinant fusion protein including two immunogenic M." exact="tuberculosis" post="antigens (Mtb32A and Mtb39A), combined with the AS01E adjuvant"/>
  <result pre="toxins approved for clinical use which include two antibodies against" exact="anthrax" post="(97, 98) and one targeting the toxin B of"/>
  <result pre="vaccine technologies and platforms. MenACWY, meningococcus ACWY; Pneumo, pneumococcus; HBV," exact="hepatitis" post="B virus; Hib, type B Haemophilus influenzae; GBS, group"/>
  <result pre="the top. Front Immunol. (2018) 9:1068. 10.3389/fimmu.2018.0106829910799 58.NicholKLNordinJDNelsonDBMulloolyJPHakE. Effectiveness of" exact="influenza" post="vaccine in the community-dwelling elderly. N Engl J Med."/>
  <result pre="J Med. (2007) 357:1373–81. 10.1056/NEJMoa07084417914038 59.KwongJCMaatenSUpshurREPatrickDMMarraF. The effect of universal" exact="influenza" post="immunization on antibiotic prescriptions: an ecological study. Clin Infect"/>
  <result pre="10.1093/jpids/piw00526907814 63.GoldsteinEFinelliLO'HalloranALiuPKaracaZSteinerCAet al.. Hospitalizations associated with respiratory syncytial virus and" exact="influenza" post="in children, including children diagnosed with asthma. Epidemiology. (2019)"/>
  <result pre="Microbiol. (2011) 9:889–93. 10.1038/nrmicro266821963800 72.RiedelSEdward Jenner and the history of" exact="smallpox" post="and vaccination. Proc (Bayl Univ Med Cent). (2005) 18:21–5."/>
  <result pre="J Hyg. (1923) 22:208–21. 10.1017/S002217240000817220474806 76.PizzaMCovacciABartoloniAPeruginiMNencioniLDe MagistrisMTet al.. Mutants of" exact="pertussis" post="toxin suitable for vaccine development. Science. (1989) 246:497–500. 10.1126/science.26830732683073"/>
  <result pre="77.van den EndeCMaranoCvan AheeABungeEMDe MoerloozeL. The immunogenicity of GSK's recombinant" exact="hepatitis" post="B vaccine in children: a systematic review of 30"/>
  <result pre="16:789–809. 10.1080/14760584.2017.133856928586278 78.NogalesAMartinez-SobridoL. Reverse genetics approaches for the development of" exact="influenza" post="vaccines. Int J Mol Sci. (2016) 18:20. 10.3390/ijms1801002028025504 79.JefferiesJMMacdonaldEFaustSNClarkeSC."/>
  <result pre="10.1126/scitranslmed.300223421753121 97.TsaiCWMorrisS. Approval of raxibacumab for the treatment of inhalation" exact="anthrax" post="under the US food and drug administration animal rule."/>
 </snippets>
</snippetsTree>
